Drug Sponsors

Janssen Labs expands to San Francisco, adds three to @LabCentral

Thursday, May 15, 2014 01:26 PM

Janssen Labs, part of Janssen R&D, plans to open Janssen Labs @South San Francisco, a new 30,000-square-foot, standalone operation based in South San Francisco, Calif. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation. Like the flagship Janssen Labs in San Diego, Janssen Labs @South San Francisco will include a combination of shared and private lab and office spaces and feature value-added solutions including operational support, education and business services. Janssen Labs @South San Francisco is scheduled to open at the end of the year.

More... »

WIRB Copernicus Group

Merck sells ophthalmology business to Santen for $600 million

Wednesday, May 14, 2014 01:33 PM

Santen Pharmaceutical has purchased Merck's ophthalmology products in Japan and key markets in Europe and Asia Pacific.

More... »


MabVax Therapeutics, Telik to merge

Wednesday, May 14, 2014 01:22 PM

MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a clinical stage oncology drug development company, have agreed to merge. MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. 

More... »

Allergan board unanimously rejects unsolicited offer from Valeant

Monday, May 12, 2014 04:08 PM

Allergan today said its board of directors has unanimously rejected the April 22 unsolicited proposal by Valeant Pharmaceuticals International. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Allergan board concluded the proposal substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan and is not in the best interests of the company and its stockholders.

More... »

Shire acquires Lumena Pharmaceuticals

Monday, May 12, 2014 12:21 PM

Shire will acquire Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for an upfront payment of $260 million in cash, plus a payment at closing and near-term contingent milestone payments related to ongoing clinical trials.

More... »

Akorn to acquire VersaPharm for $440 million

Monday, May 12, 2014 12:17 PM

Akorn, a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals, will acquire VPI Holdings, the parent company of VersaPharm, a developer and marketer of generic pharmaceuticals to niche markets within the U.S., for $440 million in cash.

More... »

Lundbeck to acquire Chelsea Therapeutics

Friday, May 9, 2014 12:25 PM

H. Lundbeck of Denmark and North Carolina-based Chelsea Therapeutics International have entered into a definitive agreement under which Lundbeck will acquire Chelsea.

More... »

Theravance to split into two companies: R&D and royalty management

Thursday, May 8, 2014 01:21 PM

Biopharmaceutical company Theravance has announced it will split into two independent, publicly traded companies via a stock dividend on May 15.

More... »

IMS Health acquires Forcea

Thursday, May 8, 2014 01:14 PM

IMS Health, a global information and technology services company, has acquired Forcea, a Belgium-based provider of business intelligence applications and analytics for hospitals and life sciences organizations.

More... »

EY report: Lack of trust keeps pharmas, payers divided on drug costs, trial data

Wednesday, May 7, 2014 02:58 PM

By Ronald Rosenberg
CenterWatch Staff Writer

The “lingering mistrust” between the pharmaceutical industry and payers over lowering drug costs and improving outcomes will make new approaches of engagement highly unlikely without a fundamental change in current approaches.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs